Abeona Therapeuti…
USUSDAbeona Therapeutics Inc (LSE:0H7R) — Biotechnology: Pharmaceutical Preparations. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie Įmonę
- Svetainė
- abeonatherapeutics.com
- Investuotojams
- investors.abeonatherapeutics.com/
- Sektorius
- Health Care · Biotechnology: Pharmaceutical Preparations
- Būstinė
- CLEVELAND, United States
- Generalinis Direktorius
- Vishwas Seshadri
- Darbuotojai
- 226
- Biržoje Nuo
- 29.01.2018 (LSE:0H7R)
- Apyvartoje Esančios Akcijos
- Laisvai Apyvartinės Akcijos
- 36.85 mln.
- Rinkos Kapitalizacija
- 282.49 mln. USD
- Insaideriai
- 10.96%
- Instituciniai Investuotojai
- 74.9%
- Šaka (SIC)
- Pharmaceutical Preparations
- P/E
- nuostolis
- P/B
- 1.97
- FCF
- −81.5 mln. USD
- Skola
- 15.0 mln. USDgrynieji pinigai
- Pelnas ir FCF – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
- NAV
Aprašymas
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Didžiausi Akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos Data |
|---|---|---|---|
| Nantahala Capital Manage… | 8.98% | 5.14 mln. | 2026-06-30 |
| Blackrock Inc. | 5.86% | 3.35 mln. | 2026-06-30 |
| Cable Car Capital, LP | 5.26% | 3.01 mln. | 2026-06-30 |
| AIGH Capital Management… | 5.22% | 2.99 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 3.87% | 2.21 mln. | 2026-06-30 |
| OneDigital Investment Ad… | 2.89% | 1.65 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.67% | 1.53 mln. | 2026-06-30 |
| AWM Investment Company,… | 2.6% | 1.49 mln. | 2026-06-30 |
| SESHADRI VISHWAS (Chief… | ≈2.25% | 1.29 mln. | 2026-09-29 |
| Geode Capital Management… | 2.21% | 1.26 mln. | 2026-06-30 |
| Kennedy Capital Manageme… | 2.17% | 1.24 mln. | 2026-06-30 |
| Goldman Sachs Group Inc | 2.14% | 1.22 mln. | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.04% | 1.17 mln. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.1% | 627 769 | 2026-06-30 |
| VAZZANO JOSEPH WALTER (C… | ≈0.84% | 482 888 | 2026-09-29 |
| Fidelity Salem Street Tr… | 0.84% | 478 770 | 2026-07-31 |
| O'MALLEY BRENDAN M (Offi… | ≈0.74% | 421 226 | 2026-09-29 |
| iShares Trust-iShares Ru… | 0.71% | 405 192 | 2026-08-31 |
| Simplify Exchange Traded… | 0.6% | 345 416 | 2026-06-30 |
| VASANTHAVADA MADHAV (Off… | ≈0.5% | 285 721 | 2026-09-29 |
| Fidelity Concord Street… | 0.48% | 273 563 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.41% | 235 632 | 2026-05-31 |
| AMOROSO MICHAEL (Directo… | ≈0.38% | 217 779 | 2026-01-26 |
| CHARLES FAITH L. (Direct… | ≈0.31% | 176 407 | 2026-01-26 |
| WUCHTERL DONALD A (Direc… | ≈0.29% | 167 935 | 2026-02-02 |
| ALLAND LEILA (Director) | ≈0.28% | 162 614 | 2026-06-30 |
| iShares Trust-iShares Mi… | 0.26% | 148 688 | 2026-08-31 |
| iShares Trust-iShares Co… | 0.21% | 119 542 | 2026-08-31 |
| SILVERSTEIN CHRISTINE BE… | ≈0.21% | 119 562 | 2026-06-15 |
| ZEIHER BERNHARDT G (Dire… | ≈0.15% | 84 458 | 2026-01-26 |
Prisijunkite su Google